Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
about
Computational systems analysis of dopamine metabolismNegative emotionality: monoamine oxidase B gene variants modulate personality traits in healthy humansAdjuvant therapies for Parkinson's disease: critical evaluation of safinamideReview of pharmacological treatment in mood disorders and future directions for drug development.MAO-B elevation in mouse brain astrocytes results in Parkinson's pathologyFrom L-dopa to dihydroxyphenylacetaldehyde: a toxic biochemical pathway plays a vital physiological function in insectsIn vitro Antioxidant and Enzymatic Approaches to Evaluate Neuroprotector Potential of Blechnum Extracts without Cytotoxicity to Human Stem CellsClose Correlation of Monoamine Oxidase Activity with Progress of Alzheimer's Disease in Mice, Observed by in Vivo Two-Photon ImagingMAOA-a novel decision maker of apoptosis and autophagy in hormone refractory neuroendocrine prostate cancer cells.Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: implications for early intervention on disease progression.Dopamine induced neurodegeneration in a PINK1 model of Parkinson's disease.Chronic L-dopa decreases serotonin neurons in a subregion of the dorsal raphe nucleusZhichan powder regulates nigrostriatal dopamine synthesis and metabolism in Parkinson's disease ratsMolecular targets of the multifunctional iron-chelating drug, M30, in the brains of mouse models of type 2 diabetes mellitus8-Benzyltetrahydropyrazino[2,1-f]purinediones: water-soluble tricyclic xanthine derivatives as multitarget drugs for neurodegenerative diseases.The reduction of R1, a novel repressor protein for monoamine oxidase A, in major depressive disorderPast, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?2-acetylphenol analogs as potent reversible monoamine oxidase inhibitors.3-Coumaranone derivatives as inhibitors of monoamine oxidase.Rapid synthesis of flavone-based monoamine oxidase (MAO) inhibitors targeting two active sites using click chemistry.M30 Antagonizes Indoleamine 2,3-Dioxygenase Activation and Neurodegeneration Induced by Corticosterone in the HippocampusThe Benzopyrone Biochanin-A as a reversible, competitive, and selective monoamine oxidase B inhibitor.Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold.Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.HIV-1, methamphetamine and astrocyte glutamate regulation: combined excitotoxic implications for neuro-AIDS.Inhibition of MAO-A and stimulation of behavioural activities in mice by the inactive prodrug form of the anti-influenza agent oseltamivirEvaluation of the Isoflavone Genistein as Reversible Human Monoamine Oxidase-A and -B InhibitorGaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5-HT in the UKEffect of Alkaloids Isolated from Phyllodium pulchellum on Monoamine Levels and Monoamine Oxidase Activity in Rat Brain.Zydis selegiline in the management of Parkinson's disease.Natural Products Screening for the Identification of Selective Monoamine Oxidase-B Inhibitors.Mechanism-based medication development for the treatment of nicotine dependence.Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?Inhibition of monoamine oxidase by (E)-styrylisatin analoguesDual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's diseasePolycyclic compounds: ideal drug scaffolds for the design of multiple mechanism drugs?Computational analysis of determinants of dopamine (DA) dysfunction in DA nerve terminals.Striatal mechanisms underlying movement, reinforcement, and punishment.Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
P2860
Q21144295-0A539E9E-9028-4EFB-8DCB-DBDC32042CF1Q24628259-C8C43133-C7F1-484E-8D7B-5271B556C424Q26766289-BFA926EC-334F-4A73-9C96-CB67A954BE5FQ26853509-9A18F08C-716A-4E30-87AC-42A211797AE2Q27301926-BD737F59-C6E1-463F-AA87-B74F82369A86Q28476804-6AC990FE-2386-4145-B3F1-DF16F5C806ADQ28829842-0B33154E-95CA-4943-BF3D-CAE7400A2C46Q30833430-E2FA99B6-B685-478C-8DB5-64873D2FF979Q33556950-7AA778E3-E9D9-4CA2-AADA-CA14B4647688Q34131429-39674FE9-19F8-4B63-949A-3795074E7528Q34291082-E6BCCFF7-14C8-4FD6-9303-37E4C0ABA727Q34360660-AA045BF1-7986-4CE0-BC8E-B66A07F31DD6Q34798682-521FB8E3-EF36-448E-A227-043630E5767BQ34914164-A8261458-BD9D-43E5-AA8D-C106FCE458A7Q35166780-F126CFD4-35A8-47DB-A379-EC7D8CE6852CQ35171311-E2BB1BEE-1943-411E-94EC-92F3D0E36B17Q35489240-F30FD55F-6693-42EF-A29E-CFCEA627B7D2Q35654026-76288B5F-01FE-4195-9564-86913A2D8E72Q35867089-44DB9453-B316-4634-916D-4CB3A5082E60Q36140140-ACF2089F-E372-422F-B60A-F0224DD22510Q36144053-2ADF3D53-31C5-4AB5-AFAB-17D16FA0FDBEQ36199834-3317495D-0EF9-48BD-9262-2CEC1ADD8EF2Q36244817-E6217E68-BF83-4CBB-B200-66717B4CA138Q36250876-7ABBDF49-6C20-4495-A8A7-CEE9FBAB3842Q36417706-C8CF8DAA-DDA2-4F62-9A34-D923480B6FDAQ36634233-93D0F4BB-F54D-429B-AF72-A2E0731404E8Q36783997-32FCD42C-A61D-4065-909D-CBE3EE9BA40CQ36784782-350B528F-0178-4343-81A0-A1FCEE781F9FQ36842508-C2325390-8683-4032-95F7-A0D8E0E8E292Q36855469-32E25324-BF03-49E9-95CA-014B4D866BC4Q36968199-A87FE7B2-B35E-4BEE-AD81-645822A73FB8Q36983563-FA9312FD-FEFB-4F7F-BD22-E76586B3FA69Q37018610-48EF585B-D64C-4BEE-B26D-8CA70657AE30Q37115650-3BF30B71-98F3-43A5-90A1-192A2984ABE1Q37218632-25CA86D6-9269-46D1-9317-D06A4FBAFB55Q37358676-7D76967D-B32F-4350-B2FA-F9F05A58409EQ37358680-823E1989-C63E-43C3-B79F-17CD92ADAA46Q37381249-8A6934BA-840B-4C30-ABC4-A017F2D6B1C8Q37431197-BC32AD00-20AE-4BBD-9275-84C23B434DCAQ37578490-E116F515-B251-4BC3-9A3B-DF90E0C63091
P2860
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
@ast
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
@en
type
label
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
@ast
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
@en
prefLabel
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
@ast
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
@en
P2860
P356
P1476
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
@en
P2093
Moussa B H Youdim
Y S Bakhle
P2860
P304
P356
10.1038/SJ.BJP.0706464
P407
P478
147 Suppl 1
P577
2006-01-01T00:00:00Z